- Home
- EXP vs LEGN Comparison
EXP vs LEGN Comparison
Compare EXP & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXP
- LEGN
- Stock Information
- Founded
- EXP 1963
- LEGN 2014
- Country
- EXP United States
- LEGN United States
- Employees
- EXP N/A
- LEGN N/A
- Industry
- EXP Building Materials
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- EXP Industrials
- LEGN Health Care
- Exchange
- EXP Nasdaq
- LEGN Nasdaq
- Market Cap
- EXP 7.3B
- LEGN 7.0B
- IPO Year
- EXP 1994
- LEGN 2020
- Fundamental
- Price
- EXP $230.08
- LEGN $31.78
- Analyst Decision
- EXP Buy
- LEGN Strong Buy
- Analyst Count
- EXP 11
- LEGN 13
- Target Price
- EXP $275.45
- LEGN $79.42
- AVG Volume (30 Days)
- EXP 301.4K
- LEGN 1.5M
- Earning Date
- EXP 05-20-2025
- LEGN 05-13-2025
- Dividend Yield
- EXP 0.43%
- LEGN N/A
- EPS Growth
- EXP N/A
- LEGN N/A
- EPS
- EXP 13.93
- LEGN N/A
- Revenue
- EXP $2,267,040,000.00
- LEGN $627,241,000.00
- Revenue This Year
- EXP $1.58
- LEGN $65.96
- Revenue Next Year
- EXP $4.92
- LEGN $52.55
- P/E Ratio
- EXP $16.53
- LEGN N/A
- Revenue Growth
- EXP 0.64
- LEGN 119.97
- 52 Week Low
- EXP $201.61
- LEGN $29.27
- 52 Week High
- EXP $321.93
- LEGN $60.87
- Technical
- Relative Strength Index (RSI)
- EXP 55.16
- LEGN 41.49
- Support Level
- EXP $222.36
- LEGN $30.25
- Resistance Level
- EXP $232.98
- LEGN $35.81
- Average True Range (ATR)
- EXP 6.82
- LEGN 1.45
- MACD
- EXP 1.10
- LEGN -0.18
- Stochastic Oscillator
- EXP 68.67
- LEGN 27.58
About EXP Eagle Materials Inc
Eagle Materials Inc produces and sells construction products and building materials. Construction products include cement, slag, concrete, and aggregates and building materials include cement and gypsum wallboard, and are sold to the construction and building industries. The firm organizes itself into two sectors: Heavy Materials, which includes the Cement and Concrete and Aggregates segments, and Light Materials, which includes the Gypsum Wallboard and Recycled Paperboard segments.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.